Patient and physician factors associated with participation in cervical and uterine cancer trials: An NRG/GOG247 study

被引:15
作者
Brooks, Sandra E. [1 ]
Carter, Randy L. [2 ,3 ,4 ]
Plaxe, Steven C. [5 ]
Basen-Engquist, Karen M. [6 ]
Rodriguez, Michael [7 ]
Kauderer, James [2 ,3 ,4 ]
Walker, Joan L. [8 ]
Myers, Tashanna K. N. [9 ]
Drake, Janet G. [10 ]
Havrilesky, Laura J. [11 ]
Van Le, Linda [12 ]
Landrum, Lisa M. [8 ]
Brown, Carol L. [13 ]
机构
[1] Norton Healthcare, Louisville, KY 40202 USA
[2] SUNY Buffalo, Buffalo, NY 14260 USA
[3] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA
[4] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[5] Rebecca & John Moores UCSD Canc Ctr, Gynecol Oncol, La Jolla, CA 92093 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA
[7] Mem Hosp, Northern Indiana Canc Res Consortium, Gynecol Oncol, Mishawaka, IN 46545 USA
[8] Univ Oklahoma, Gynecol Oncol, Oklahoma City, OK 73104 USA
[9] Baystate Med Ctr, GYN ONC, Springfield, MA 01199 USA
[10] Waukesha Mem Hosp, Gynecol Oncol, Waukesha, WI USA
[11] Duke Univ, Med Ctr, OB GYN, Durham, NC 27710 USA
[12] Univ Norton Carolina, Gynecol Oncol, Chapel Hill, NC USA
[13] Mem Sloan Kettering Canc Ctr, Off Divers Programs Clin Care Res & Training, New York, NY 10065 USA
关键词
Clinical trial enrollment; Patient and physician factors; Gynecologic Oncology Group; NRG Oncology; Cervical cancer trials; Uterine cancer trials; Minority enrollment; SPONSORED CLINICAL-TRIALS; MINORITY PARTICIPATION; ETHNIC-MINORITIES; RECRUITMENT; COMMUNITY; WILLINGNESS; PREVENTION; EXPERIENCE; ENROLLMENT; BARRIERS;
D O I
10.1016/j.ygyno.2015.04.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. The aim of this study was to identify patient and physician factors related to enrollment onto Gynecologic Oncology Group (GOG) trials. Methods. Prospective study of women with primary or recurrent cancer of the uterus or cervix treated at a GOG institution from July 2010 to January 2012. Logistic regression examined probability of availability, eligibility and enrollment in a GOG trial. Odds ratios (OR) and 95% confidence intervals (Cl) for significant (p < 0.05) results reported. Results. Sixty institutions, 781 patients, and 150 physicians participated, 300/780 (38%) had a trial available, 290/300 had known participation status. Of these, 150 women enrolled (59.5%), 102 eligible did not enroll (35%), 38 (13%) were ineligible. Ethnicity and specialty of physician, practice type, data management availability, and patient age were significantly associated with trial availability. Patients with >4 comorbidities (OR 4.5; CI 1.7-11.8) had higher odds of trial ineligibility. Non-White patients (OR 7.9; Cl 1.3-46.2) and patients of Black physicians had greater odds of enrolling (OR 56.5; Cl 1.1-999.9) in a therapeutic trial. Significant patient therapeutic trial enrollment factors: belief trial may help (OR 76.9; Cl 4.9->1000), concern about care if not on trial (OR12.1; Cl 2.1-71.4), pressure to enroll (OR.27; Cl 0.12-.64), caregiving without pay (OR 0.13; Cl.02-.84). Significant physician beliefs were: patients would not do well on standard therapy (OR 3.6; Cl 1.6-8.4), and trial would not be time consuming (OR 33; Cl 13-8.1). Conclusions. Trial availability, patient and physician beliefs were factors identified that if modified could improve enrollment in cancer cooperative group clinical trials. (C) 2015 The Authors. Published by Elsevier Inc.
引用
收藏
页码:101 / 108
页数:8
相关论文
共 34 条
[1]  
[Anonymous], RACIAL ETHNIC MINORI
[2]  
[Anonymous], 2010, NATL CANC CLIN TRIAL
[3]   Analysis of Maryland cancer patient participation in National Cancer Institute-supported cancer treatment clinical trials [J].
Baquet, Claudia R. ;
Ellison, Gary L. ;
Mishra, Shiraz I. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3380-3386
[4]   Recruitment and participation in clinical trials: Socio-demographic, rural/urban, and health care access predictors [J].
Baquet, CR ;
Commiskey, P ;
Mullins, CD ;
Mishra, SI .
CANCER DETECTION AND PREVENTION, 2006, 30 (01) :24-33
[5]   Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials [J].
Braunstein, Joel B. ;
Sherber, Noelle S. ;
Schulman, Steven P. ;
Ding, Eric L. ;
Powe, Neil R. .
MEDICINE, 2008, 87 (01) :1-9
[6]   Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989-1999 [J].
Brooks, BE ;
Zhan, M ;
Cote, T ;
Baquet, CR .
GYNECOLOGIC ONCOLOGY, 2004, 93 (01) :204-208
[7]   Resource utilization for patients undergoing hysterectomy with or without lymph node dissection for endometrial cancer [J].
Brooks, SE ;
Mullins, CD ;
Guo, CF ;
Chen, TT ;
Gardner, JF ;
Baquet, CR .
GYNECOLOGIC ONCOLOGY, 2002, 85 (02) :242-249
[8]   Recruitment and retention of minority women in cancer screening, prevention, and treatment trials [J].
Brown, DR ;
Fouad, MN ;
Basen-Engquist, K ;
Tortolero-Luna, G .
ANNALS OF EPIDEMIOLOGY, 2000, 10 (08) :S13-S21
[9]   Participation in Cancer Clinical Trials: Why Are Patients Not Participating? [J].
Byrne, Margaret M. ;
Tannenbaum, Stacey L. ;
Gluck, Stefan ;
Hurley, Judith ;
Antoni, Michael .
MEDICAL DECISION MAKING, 2014, 34 (01) :116-126
[10]   Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP-Sponsored Clinical Trials [J].
Cheng, Steven K. ;
Dietrich, Mary S. ;
Dilts, David M. .
CLINICAL CANCER RESEARCH, 2011, 17 (07) :1947-1955